FIRST GENOMIC INSIGHTS
FIRST GENOMIC INSIGHTS

First Genomic Insights

About Us

Paradigm Shift

Non-Invasive Fetal Sequencing (NIFS) Platform

Non-Invasive Fetal Sequencing (NIFS) Platform

FGI plans to introduce a paradigm shift in prenatal genomics by integrating advanced sequencing technologies with deep expertise across fetal, pediatric, clinical, and population genomics. FGI aims to move beyond limited prenatal testing using gene panels toward comprehensive clinical genomic screening.

Non-Invasive Fetal Sequencing (NIFS) Platform

Non-Invasive Fetal Sequencing (NIFS) Platform

Non-Invasive Fetal Sequencing (NIFS) Platform

FGI has developed a first-of-its-kind non-invasive fetal sequencing (NIFS) platform capable using maternal blood to screen ~23,000 fetal genes and identify clinically relevant genetic variation that may impact fetal and maternal health. We are establishing strategic international partnerships with leading commercial laboratories to expand the global delivery of NIFS technologies.

Our Mission

FGI will redefine prenatal care by engineering scalable and comprehensive non-invasive genomic technologies to deliver clinically relevant genetic information to patients.


FGI is not just improving tests — we’re transforming the future of maternal-fetal medicine with innovations built on validated technologies and data science, engineered with precision, and developed with deep expertise in real-world clinical implementation. 


We are building the infrastructure for a new standard of prenatal care—one that replaces fragmented, narrow testing paradigms with scientifically rigorous, genome-scale precision medicine. Our goal is to responsibly translate decades of genomic expertise into information that drives meaningful improvements in maternal, fetal, newborn, and pediatric health.


Founded by scientific and clinical leaders, we are building the future rigorously and responsibly to improve clinical care.

Our Founders

Michael Talkowski, PhD

Michael Talkowski, PhD

Michael Talkowski, PhD

Co-Founder

Director, Center for Genomic Medicine

Massachusetts General Hospital

Broad Institute of MIT and Harvard

Harvard Medical School

Wendy Chung, MD, PhD

Michael Talkowski, PhD

Michael Talkowski, PhD

Co-Founder

Chief of Pediatrics

Boston Children’s Hospital

 Harvard Medical School

Ronald Wapner, MD

Michael Talkowski, PhD

Ronald Wapner, MD

Co-Founder

Director of Women’s Genetics

Columbia University Irving Medical Center

FGI is a biotechnology company founded by physicians to serve as a healthcare delivery platform for prenatal genomic medicine.

Our founders are lifelong healthcare providers and genomic medicine leaders who have pioneered the translation of genetics into clinical care for fetuses, newborns, children, and adults. 


For over a decade, we have worked to move maternal–fetal genomic medicine beyond narrow panels and partial answers. While much of the current market promotes “expanded” care, many existing technologies evaluate only a small fraction of clinically reportable conditions accessible to genomics technologies. We started FGI to fundamentally change that trajectory.

Technology

Backed by decades of Genomic medicine research

Comprehensive in scientific scope

Responsible and transparent in implementation

Cutting-edge in technology and data science

Cutting-edge in technology and data science

Responsible and transparent in implementation

Cutting-edge in technology and data science

Clinically grounded in real-world care

Responsible and transparent in implementation

Responsible and transparent in implementation

Responsible and transparent in implementation

Responsible and transparent in implementation

Responsible and transparent in implementation

FGI Operates at the intersection of biotechnology and healthcare delivery.

Contact Us

    

View Our NEJM Publication

Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Copyright © 2026 First Genomic Insights - All Rights Reserved.